Combining familial hypercholesterolemia and statin genetic studies as a strategy for the implementation of pharmacogenomics. A multidisciplinary approach

• Published in: The pharmacogenomics journal Vol. 22; no. 3; pp. 180 - 187
• Main Authors: Ramudo-Cela, Luis, Santana-Martínez, Sara, García-Ramos, Maite, Bergamino, Mariano, García-Giustiniani, Diego, Vélez-Vieitez, Paula, Hernández-Hernández, Jose Luis, García-Ibarbia, Carmen, González-Bustos, Pablo, Ruíz-Martín, Patricia, González-Lozano, Jaime, Santomé-Collazo, Luis, Grana-Fernandez, Andrea, Cabaleiro-Cerviño, Pablo, Ortíz, Martín, Monserrat-Iglesias, Lorenzo
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01-05-2022; Nature Publishing Group
• Subjects: 631/208/212/1728; 631/208/212/2166; 631/208/2489/1512; 692/700/228; Atorvastatin; Biomedical and Life Sciences; Biomedicine; Clinical medicine; Fluvastatin; Gene Expression; Genotypes; Human Genetics; Hypercholesterolemia; Knowledge management; Lovastatin; Oncology; Patients; Pharmacogenomics; Pharmacotherapy; Psychopharmacology; Simvastatin; Statins
• ISSN: 1470-269X; 1473-1150
• DOI: 10.1038/s41397-022-00274-8

The diagnostic process of familial hypercholesterolemia frequently involves the use of genetic studies. Patients are treated with lipid-lowering drugs, frequently statins. Although pharmacogenomic clinical practice guidelines focusing on genotype-based statin prescription have been published, their use in routine clinical practice remains very modest.
We have implemented a new NGS strategy that combines a panel of genes related to familial hypercholesterolemia with genomic regions related to the pharmacogenomics of lipid-lowering drugs described in clinical practice guidelines and in EMA and FDA drug labels. A multidisciplinary team of doctors, biologists, and pharmacists creates a clinical report that provides diagnostic and therapeutic findings using a knowledge management and clinical decision support system, as well as an algorithm for treatment selection.
For 12 months, a total of 483 genetic diagnostic studies for familial hypercholesterolemia were carried out, of which 221 (45.8%) requested a complementary pharmacogenomic test. Of these 221 patients, 66.5% were carriers of actionable variants in any of the studied pharmacogenomic pathways: 46.6% of patients in one pathway, 19.0% in two pathways, and 0.9% in three pathways. 45.7% of patients could have a response to atorvastatin different from that of the reference population, 45.7% for simvastatin and lovastatin, 29.0% for fluvastatin, and 6.7% patients for pitavastatin.
This implementation approach facilitates the incorporation of pharmacogenomic studies in clinical care practice, it does not add complexity nor additional steps to laboratory processes, and improves the pharmacotherapeutic process of patients.